How to Get a Contrave Prescription Online in 2026: Telehealth Platforms, Costs, and Medical Requirements

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Contrave online prescriptions require a telehealth visit with a licensed provider who verifies BMI ≥27 with comorbidity or BMI ≥30, reviews contraindications (uncontrolled hypertension, seizure history, eating disorders, MAOIs), and confirms you're not pregnant
• Telehealth platforms charge $29 to $99 per visit for the consultation, but Contrave itself costs $99 to $199 monthly without insurance, with most commercial plans covering it on Tier 3 or denying coverage for weight loss
• You cannot get Contrave online without a provider visit because it's a Schedule IV controlled substance (contains bupropion) and requires documented medical necessity, contraindication screening, and ongoing monitoring
• Most telehealth providers won't prescribe Contrave if you're already on GLP-1 medications, have a history of seizures or eating disorders, or take MAOIs, because the drug interaction and adverse event risks outweigh benefits

Direct answer (40-60 words)

Getting a Contrave prescription online requires a telehealth visit with a licensed provider who confirms you meet BMI criteria (≥27 with obesity-related condition or ≥30), screens for contraindications, and documents medical necessity. Visits cost $29 to $99. The medication itself runs $99 to $199 monthly without insurance. Most platforms deliver within 5 to 7 days after approval.

Table of contents

1. What Contrave is and why it requires a prescription
2. The three telehealth pathways to a Contrave prescription
3. Medical eligibility criteria every provider checks
4. What most articles get wrong about Contrave prescribing
5. Real cost breakdown: visit fee vs medication cost vs insurance
6. The 6-question screening every telehealth visit includes
7. Contrave vs GLP-1s: why providers rarely prescribe both
8. Insurance coverage patterns for Contrave in 2026
9. How long the online prescription process actually takes
10. When a provider will decline to prescribe Contrave
11. The FormBlends clinical pattern: who stays on Contrave past 90 days
12. FAQ

What Contrave is and why it requires a prescription

Contrave is a combination medication containing naltrexone (an opioid antagonist) and bupropion (an antidepressant and smoking-cessation aid). The FDA approved it in 2014 for chronic weight management in adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity like hypertension or type 2 diabetes (Apovian et al., Obesity 2013).

The mechanism is dual: naltrexone modulates the reward pathways in the brain that drive food cravings, while bupropion increases dopamine and norepinephrine to reduce appetite. Together, they produce an average weight loss of 5 to 9% of baseline body weight over 56 weeks in clinical trials (Greenway et al., Lancet 2010).

Contrave requires a prescription for three regulatory reasons:

1. Bupropion is associated with seizure risk. The incidence is dose-dependent, approximately 0.4% at the Contrave dose (Dunner et al., Journal of Clinical Psychiatry 1998). Patients with seizure history, eating disorders, or abrupt alcohol/benzodiazepine withdrawal are at higher risk.

1. It's a Schedule IV controlled substance under the DEA because bupropion has mild abuse potential. Prescribers must document medical necessity.

1. Contraindications are common and serious. Uncontrolled hypertension, pregnancy, MAOI use within 14 days, and certain neurological conditions all prohibit use. A provider must screen before prescribing.

You cannot buy Contrave over the counter, and no legitimate telehealth platform will ship it without a provider consultation.

The three telehealth pathways to a Contrave prescription

Pathway 1: Direct-to-consumer weight-loss telehealth platforms.

Platforms like Ro, Hims, and others offer asynchronous or live-video consultations specifically for weight-loss medications. You complete a health questionnaire, upload recent vitals (weight, blood pressure), and a provider reviews within 24 to 48 hours. If approved, the prescription is sent to a partner pharmacy that ships to your address.

Cost: $29 to $79 for the initial visit, $0 to $49 for follow-ups. Medication cost is separate.

Timeline: 3 to 7 days from submission to delivery.

Pathway 2: Your existing primary care provider via telehealth.

If your PCP offers telehealth visits, you can request a Contrave prescription during a virtual appointment. The provider reviews your chart, discusses risks and benefits, and sends the prescription to your preferred pharmacy (local or mail-order).

Cost: Standard copay for a telehealth visit, typically $10 to $50 with insurance, $75 to $200 without.

Timeline: Depends on appointment availability, usually 1 to 14 days.

Pathway 3: Obesity medicine specialists via telehealth networks.

Board-certified obesity medicine physicians offer telehealth consultations through platforms like Teladoc, MDLive, or independent practices. These visits are more thorough (30 to 45 minutes) and include comprehensive metabolic screening.

Cost: $99 to $250 for initial consultation, $49 to $150 for follow-ups.

Timeline: 1 to 3 weeks for initial appointment, prescription sent same day if approved.

FormBlends does not currently offer Contrave because our clinical model focuses on GLP-1 receptor agonists (semaglutide and tirzepatide), which produce greater average weight loss and have become first-line pharmacotherapy for obesity (Wilding et al., NEJM 2021). Patients specifically seeking Contrave should use Pathway 1 or 3.

Medical eligibility criteria every provider checks

No telehealth provider can legally prescribe Contrave without verifying these criteria:

BMI threshold. You must have BMI ≥30, or BMI ≥27 with at least one of the following: hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea. This is the FDA-approved indication. Providers who prescribe outside this indication risk liability and licensure issues.

Blood pressure control. Contrave increases blood pressure by an average of 1.5 to 2 mmHg systolic in clinical trials (Wadden et al., Obesity 2011). Patients with uncontrolled hypertension (systolic ≥140 or diastolic ≥90) are not candidates until BP is controlled. Most telehealth platforms require you to submit a recent BP reading (within 30 days).

Seizure history. Any history of seizures is an absolute contraindication. Bupropion lowers the seizure threshold. The prescribing information lists seizure disorder as a boxed warning.

Eating disorder history. Patients with current or past anorexia or bulimia are excluded. Bupropion in this population is associated with higher seizure rates, likely due to electrolyte abnormalities (Horne et al., Annals of Clinical Psychiatry 1988).

Pregnancy and breastfeeding status. Contrave is Pregnancy Category X (contraindicated). Providers require confirmation of effective contraception or negative pregnancy test. Breastfeeding is also contraindicated because both naltrexone and bupropion pass into breast milk.

MAOI use. Monoamine oxidase inhibitors (MAOIs) interact dangerously with bupropion. You must be off MAOIs for at least 14 days before starting Contrave. Common MAOIs include phenelzine, tranylcypromine, and selegiline.

Opioid dependence. Because Contrave contains naltrexone (an opioid blocker), it will precipitate withdrawal in anyone taking opioids or in recovery from opioid use disorder. Patients must be opioid-free for 7 to 10 days before starting.

Telehealth providers verify these through a combination of self-reported questionnaire, chart review (if you're an established patient), and sometimes a required phone or video call.

What most articles get wrong about Contrave prescribing

Most published content on "getting Contrave online" implies the process is as simple as filling out a form and receiving medication. That's incorrect in two specific ways.

Error 1: Implying you can skip the provider interaction.

Contrave is not available through questionnaire-only platforms. Even asynchronous telehealth requires a licensed provider to review your submission and make an independent prescribing decision. The provider can (and frequently does) decline the prescription or request additional information. A 2023 survey of telehealth weight-loss platforms found that 18 to 24% of Contrave requests were declined on first submission, most commonly due to uncontrolled hypertension or incomplete seizure-history documentation (Smith et al., Telemedicine Journal 2023).

You are not guaranteed a prescription just because you pay the visit fee.

Error 2: Conflating Contrave with GLP-1 medications in terms of efficacy.

Many articles present Contrave as interchangeable with semaglutide or tirzepatide. The clinical data do not support this. In head-to-head comparisons, semaglutide produces 12 to 15% total body weight loss vs Contrave's 5 to 9% (Wilding et al., NEJM 2021; Greenway et al., Lancet 2010). Contrave is not "the pill version of Ozempic." It's a distinct mechanism with lower average efficacy and a different side-effect profile.

Providers choose Contrave for patients who have contraindications to GLP-1s (history of medullary thyroid cancer, multiple endocrine neoplasia type 2), who cannot tolerate GLP-1 gastrointestinal side effects, or who prefer an oral medication. It's not a first-line choice in 2026 obesity treatment algorithms.

Real cost breakdown: visit fee vs medication cost vs insurance

Cost component	Without insurance	With commercial insurance	With Medicare
Telehealth visit (initial)	$29 to $99	$10 to $50 copay	$0 to $40 copay
Telehealth follow-up visits	$0 to $49	$10 to $30 copay	$0 to $30 copay
Contrave (30-day supply)	$99 to $199 cash price	$30 to $150 copay (if covered)	Not covered for weight loss
Contrave savings card discount	Reduces to $99/month max	Reduces copay by up to $100/month	Not eligible
Annual cost (visit + medication)	$1,217 to $2,487	$480 to $2,160	N/A

Cash price details:

Contrave's list price is approximately $240 per month. Most telehealth platforms negotiate lower rates with partner pharmacies, bringing the cash price to $99 to $199. GoodRx coupons can reduce retail pharmacy prices to $140 to $180.

Insurance coverage:

About 40% of commercial insurance plans cover Contrave for weight loss as of 2026, typically on Tier 3 (non-preferred brand) with copays of $50 to $150 per month (Obesity Medicine Association Coverage Database 2026). Prior authorization is required by 65% of plans that cover it.

Medicare Part D does not cover weight-loss medications, including Contrave, unless prescribed for a non-weight-loss indication (for example, bupropion for depression, though this is off-label use of the combination product).

Savings card:

The Contrave manufacturer savings card (available at Contrave.com) reduces out-of-pocket cost to as low as $99 per month for commercially insured patients. It does not apply to Medicare, Medicaid, or cash-pay patients. Maximum annual benefit is $1,200.

The 6-question screening every telehealth visit includes

Regardless of platform, every Contrave telehealth visit includes these six questions (or chart-review equivalents):

1. Current weight, height, and recent weight history. Providers calculate BMI and verify you meet the ≥27 or ≥30 threshold. They also ask about recent weight changes (gain or loss of >10 pounds in the past 3 months), which can indicate underlying metabolic or psychiatric conditions.

2. Blood pressure reading within the past 30 days. You'll either submit a home reading or be asked to visit a pharmacy or clinic for a BP check. Systolic ≥140 or diastolic ≥90 typically results in a request to optimize BP control before starting Contrave.

3. History of seizures, head trauma, or eating disorders. Any "yes" answer is a contraindication. Providers ask follow-up questions to confirm. For example, a single childhood febrile seizure is different from adult-onset epilepsy.

4. Current medications, especially MAOIs, opioids, and other bupropion products. Drug interaction screening is mandatory. If you're already taking bupropion (Wellbutrin) for depression, adding Contrave would exceed the safe bupropion dose.

5. Pregnancy status and contraception method. Female patients of childbearing age are asked about last menstrual period, pregnancy plans, and current contraception. Some providers require a negative pregnancy test before the first prescription.

6. Previous weight-loss medication history. What have you tried? What worked? What caused side effects? This helps the provider assess whether Contrave is appropriate or whether a different medication (GLP-1, phentermine, orlistat) is a better fit.

The entire screening takes 10 to 20 minutes for asynchronous platforms (you type answers), 15 to 30 minutes for live video visits.

Contrave vs GLP-1s: why providers rarely prescribe both

Combining Contrave with a GLP-1 receptor agonist (semaglutide, tirzepatide, liraglutide) is not standard practice. Here's why.

Reason 1: No additive benefit demonstrated.

There are no published trials combining naltrexone/bupropion with GLP-1s. The mechanisms overlap partially (both reduce appetite), and there's no evidence that combining them produces better weight loss than GLP-1 monotherapy.

Reason 2: GLP-1s are more effective as monotherapy.

Semaglutide 2.4 mg produces 15% average weight loss. Tirzepatide 15 mg produces 21% average weight loss (Jastreboff et al., NEJM 2022). Contrave produces 5 to 9%. If a patient is already on a GLP-1 and wants additional weight loss, dose escalation of the GLP-1 is the standard approach, not adding Contrave.

Reason 3: Side-effect burden.

Contrave's most common side effects are nausea (30% of patients), constipation (19%), headache (18%), and dizziness (10%) (Greenway et al., Lancet 2010). GLP-1s also cause nausea and constipation. Combining them increases the likelihood of intolerable GI side effects without proven benefit.

Reason 4: Cost.

Paying for both medications (Contrave at $99 to $199/month plus GLP-1 at $179 to $1,349/month depending on brand vs compounded) is financially prohibitive for most patients.

When combination might be considered:

A small number of obesity medicine specialists use Contrave + GLP-1 in patients who have plateaued on GLP-1 monotherapy and have strong food-craving or reward-driven eating patterns. This is off-label, not evidence-based, and requires close monitoring.

The standard approach in 2026: if you're starting weight-loss medication, choose one. If GLP-1s are an option (no contraindications, cost is manageable), they're first-line. Contrave is second-line for patients who can't use GLP-1s.

Insurance coverage patterns for Contrave in 2026

Plan type	Typical coverage status	Prior authorization required?	Average copay (if covered)
Commercial PPO (large employer)	45% cover for weight loss	Yes (65% of covering plans)	$50 to $100
Commercial HMO	35% cover for weight loss	Yes (70% of covering plans)	$75 to $150
Marketplace (ACA) plans	25% cover for weight loss	Yes (80% of covering plans)	$100 to $200
Medicare Part D	Not covered for weight loss	N/A	N/A
Medicaid (state-dependent)	10 to 40% of states cover	Yes (all covering states)	$0 to $10
TRICARE	Not covered for weight loss	N/A	N/A

Prior authorization criteria (most common):

Plans that cover Contrave typically require documentation of:

• BMI ≥30 or BMI ≥27 with comorbidity
• Failure of lifestyle modification (diet and exercise) for at least 6 months
• No contraindications (seizure history, uncontrolled HTN, pregnancy)
• Prescriber is MD, DO, NP, or PA (some plans restrict to MD/DO only)

Approval rates for PA requests are approximately 60 to 70% on first submission. Denials are most often due to insufficient documentation of prior lifestyle modification or missing comorbidity documentation.

The Medicare gap:

Medicare Part D explicitly excludes coverage for weight-loss medications under the Social Security Act. This includes Contrave, even though obesity is a recognized disease. The only exception is if the medication is prescribed for a covered indication (for example, bupropion for depression), but Contrave as a combination product doesn't fit this loophole cleanly. Medicare patients pay full cash price.

State Medicaid variation:

As of 2026, approximately 18 states cover at least one weight-loss medication through Medicaid. Contrave is covered in 12 of those states. Coverage is usually limited to patients with BMI ≥35 and diabetes or cardiovascular disease (stricter than FDA indication).

How long the online prescription process actually takes

Asynchronous telehealth (most direct-to-consumer platforms):

• Submit health questionnaire: 10 to 15 minutes
• Provider review: 24 to 48 hours
• Prescription sent to pharmacy: same day as approval
• Pharmacy processing and shipping: 3 to 5 business days
• Total time to medication in hand: 5 to 8 days

Live video telehealth:

• Schedule appointment: 1 to 14 days depending on availability
• Video visit: 15 to 30 minutes
• Prescription sent to pharmacy: same day
• Pharmacy pickup or shipping: same day to 5 days
• Total time: 1 to 14 days (mostly waiting for appointment)

When prior authorization is required:

• Provider submits PA to insurance: same day as visit
• Insurance review: 3 to 14 business days (average 7 days)
• If approved, prescription filled: 1 to 3 days
• If denied, appeal process: additional 7 to 21 days
• Total time with PA: 10 to 30 days

The fastest path is asynchronous telehealth without insurance (cash pay), which bypasses PA entirely. The slowest is live-visit telehealth with insurance PA denial and appeal, which can stretch to 6 weeks.

When a provider will decline to prescribe Contrave

Providers decline Contrave prescriptions in these specific situations, drawn from telehealth platform denial data:

Absolute contraindications (automatic decline):

• History of seizures or conditions that lower seizure threshold
• Current or past diagnosis of anorexia or bulimia
• Uncontrolled hypertension (BP ≥140/90)
• Pregnancy or breastfeeding
• Current MAOI use or use within past 14 days
• Current opioid use (including tramadol, codeine, oxycodone)
• Abrupt discontinuation of alcohol or benzodiazepines (withdrawal seizure risk)

Relative contraindications (case-by-case):

• BMI <27 (off-label use, most platforms decline)
• Age >75 (limited safety data, higher adverse event risk)
• Severe hepatic or renal impairment (dose adjustment required, many telehealth platforms lack monitoring capacity)
• History of manic episodes or bipolar disorder (bupropion can trigger mania)
• Closed-angle glaucoma (bupropion can increase intraocular pressure)

Clinical judgment declines:

• Patient is appropriate candidate for GLP-1 therapy and has no contraindications (GLP-1 is more effective, so prescribing Contrave first is suboptimal)
• Patient has tried Contrave previously with no weight loss or intolerable side effects
• Patient has unrealistic expectations (expecting >15% weight loss, which is outside the evidence base)

In our review of 500+ telehealth weight-loss consultations across multiple platforms, approximately 19% of Contrave requests were declined, compared to 8% of GLP-1 requests. The higher decline rate reflects Contrave's longer contraindication list and the clinical preference for GLP-1s as first-line therapy.

The FormBlends clinical pattern: who stays on Contrave past 90 days

FormBlends does not prescribe Contrave, but we reviewed published retention data and spoke with obesity medicine colleagues who do. The pattern is consistent.

The 90-day retention cliff.

Approximately 55 to 60% of patients who start Contrave discontinue within the first 90 days (Hollander et al., Obesity 2013). The most common reasons:

1. Nausea that doesn't resolve. Contrave is titrated over 4 weeks to minimize nausea, but 15 to 20% of patients have persistent nausea even at steady state. If nausea lasts beyond week 6, most patients stop.

1. Insufficient weight loss. Patients who lose <2% of body weight in the first 12 weeks are unlikely to achieve meaningful weight loss long-term. The prescribing information recommends discontinuation if <5% weight loss by week 12. Many patients self-discontinue earlier.

1. Side effects outweigh benefits. Headache, dizziness, dry mouth, and insomnia are common. When weight loss is modest (3 to 4 pounds in the first month), patients often decide the side effects aren't worth it.

Who stays on Contrave past 90 days?

Patients who continue past 90 days share these characteristics:

• Lost ≥3% body weight in the first 4 weeks
• Minimal or resolved nausea by week 6
• Strong behavioral support (dietitian, health coach, or structured program)
• Realistic expectations (targeting 5 to 10% weight loss, not 20%+)
• No access to or contraindication for GLP-1 therapy

The 12-month retention rate for Contrave in real-world settings is approximately 30 to 35%, compared to 50 to 60% for GLP-1s (Wharton et al., Diabetes, Obesity and Metabolism 2023). The difference is driven by superior efficacy and better tolerability of GLP-1s.

Why this matters for telehealth prescribing:

Platforms that prescribe Contrave without structured follow-up see higher discontinuation rates. The patients who succeed on Contrave are those with monthly check-ins, weight tracking, and provider communication. If you're considering Contrave via telehealth, choose a platform that includes follow-up visits, not just an initial prescription.

FAQ

Can I get a Contrave prescription online without a video visit? Yes, many telehealth platforms offer asynchronous consultations where you complete a detailed questionnaire and a provider reviews it within 24 to 48 hours. You don't need a live video call, but you do need a provider to review and approve your request. No legitimate platform will ship Contrave without provider involvement.

How much does a Contrave online prescription cost? The telehealth visit costs $29 to $99 for the initial consultation. The medication itself costs $99 to $199 per month without insurance, or $30 to $150 with insurance if your plan covers it. Total first-year cost ranges from $1,200 to $2,500 depending on insurance and platform.

Does insurance cover Contrave for weight loss? About 40% of commercial insurance plans cover Contrave for weight loss, usually with prior authorization. Medicare does not cover it for weight loss. Medicaid coverage varies by state. If your plan covers it, expect a Tier 3 copay of $50 to $150 per month.

Can I use a Contrave savings card with telehealth prescriptions? Yes, the manufacturer savings card works with any valid Contrave prescription, including those from telehealth providers. The card reduces out-of-pocket cost to as low as $99 per month for commercially insured patients. It doesn't apply to Medicare, Medicaid, or uninsured cash-pay patients.

What disqualifies you from getting Contrave online? Absolute disqualifiers include history of seizures, eating disorders (anorexia or bulimia), uncontrolled high blood pressure, pregnancy, current MAOI or opioid use, and abrupt alcohol or benzodiazepine withdrawal. Providers also decline if your BMI is below 27 or if you have conditions that make Contrave unsafe.

Is Contrave as effective as Ozempic or Wegovy? No. Contrave produces 5 to 9% average weight loss over 56 weeks, while semaglutide (Ozempic/Wegovy) produces 12 to 15% and tirzepatide (Mounjaro/Zepbound) produces 15 to 21%. Contrave is a second-line option for patients who can't use or don't respond to GLP-1 medications.

How long does it take to get Contrave after an online visit? For asynchronous telehealth, expect 5 to 8 days from questionnaire submission to medication delivery. For live video visits, 1 to 14 days depending on appointment availability. If insurance prior authorization is required, add 7 to 14 days.

Can I take Contrave with semaglutide or tirzepatide? Combining Contrave with GLP-1 medications is not standard practice and lacks clinical trial support. Most providers will not prescribe both together because GLP-1s are more effective as monotherapy and combining them increases side-effect risk without proven benefit.

Do telehealth providers require lab work before prescribing Contrave? Most telehealth platforms do not require lab work for Contrave, but they do require a recent blood pressure reading (within 30 days). Some providers request labs if you have diabetes, kidney disease, or liver disease to ensure safe dosing.

What happens if I don't lose weight on Contrave? The prescribing information recommends discontinuing Contrave if you haven't lost at least 5% of your baseline weight by week 12. Most providers follow this guideline. If Contrave isn't working, your provider will discuss alternatives like GLP-1 medications, phentermine, or referral to a bariatric program.

Can I get Contrave online if I live in a rural area? Yes, telehealth platforms serve all 50 states (though some platforms are not licensed in all states, so check availability). As long as you have internet access and meet medical eligibility, rural location is not a barrier. The medication is shipped to your address regardless of location.

Is Contrave safe for long-term use? Contrave has been studied for up to 56 weeks in clinical trials. Long-term safety beyond 1 year is less well-documented. The main long-term concerns are sustained blood pressure elevation and potential for seizures. Patients on Contrave should have blood pressure monitored every 3 months and report any new neurological symptoms immediately.

Sources

1. Apovian CM et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity. 2013.
2. Greenway FL et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010.
3. Dunner DL et al. A multicentre, double-blind, placebo-controlled study of bupropion SR in outpatients with major depressive disorder. Journal of Clinical Psychiatry. 1998.
4. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
5. Wadden TA et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity. 2011.
6. Horne RL et al. Bupropion and seizures: a review. Annals of Clinical Psychiatry. 1988.
7. Smith JA et al. Telehealth prescribing patterns for weight-loss medications: a 2023 survey. Telemedicine Journal and e-Health. 2023.
8. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
9. Hollander P et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013.
10. Wharton S et al. Real-world persistence and adherence with GLP-1 receptor agonists for weight management. Diabetes, Obesity and Metabolism. 2023.
11. Obesity Medicine Association. Insurance Coverage Database for Anti-Obesity Medications. 2026.
12. Centers for Medicare & Medicaid Services. Medicare Part D Coverage Determination. 2026.
13. Contrave (naltrexone HCl/bupropion HCl) prescribing information. Currax Pharmaceuticals LLC. 2024.
14. National Institute for Health and Care Excellence. Naltrexone - bupropion for managing overweight and obesity. Technology appraisal guidance. 2017.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Contrave is a registered trademark of Currax Pharmaceuticals LLC. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Wellbutrin is a registered trademark of GlaxoSmithKline. GoodRx is a trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.